• Embedd

  Participated · Seed · Aug 2026

  Embedd develops a platform that turns chip documentation into digital twins of hardware to accelerate software integration across devices such as robots, vehicles, drones and medical devices. The company says its platform reduces firmware and integration timelines from months to roughly three weeks and can deliver production-ready software for a given chip up to six times faster than manual processes. Embedd launched commercially in April 2026 and has already signed semiconductor customers, including Microchip Technology, to enable support for ecosystems like the Zephyr real-time operating system. The startup was founded by Ukrainian entrepreneurs Michael Lazarenko, Maxim Gorinov, and Valentin Gololobov, who previously ran a hardware company together. With the $2.7 million pre-seed funding led by Seedcamp, Embedd plans to expand its platform and deepen partnerships with semiconductor companies as it pursues broader adoption in robotics, automotive, manufacturing and medical device markets.

• Crewline AI

  Participated · Seed · Apr 2026

  Crewline AI builds a hardware‑autonomy stack that retrofits standard vibratory rollers into autonomous machines that perform soil and asphalt compaction within geo‑fenced zones. The company has completed site deployments with contractors such as Dynamic Site Solutions and Watts Services, reporting significant reductions in site downtime and doubling productive hours during initial 30‑day trials. Crewline is led by CEO Frederik Filz‑Reiterdank and CTO Mohamed Sadek and is based in San Francisco, California. The startup raised $7.1M in a seed round led by Initialized Capital and Nebular, with participation from Ford Street Ventures, Cocoa, Begin, Entrepreneurs First (EF), Transpose, and various angel investors. Crewline plans to use the seed capital to scale its fleet of self‑driving rollers and aims to deploy 100 units on earthwork jobs within the current year. The company targets retrofitting existing construction machinery rather than replacing fleets wholesale.

• Calibre

  Participated · Seed · Apr 2026

  Calibre offers a clinician-led service that connects medical history, daily behaviours and environmental context with diagnostics and causal AI to identify drivers of an individual's health and provide personalised plans. It launches a new category it calls Causal Health Navigation and is positioning itself as a proactive health partner available from £69 a month. The company emerged from stealth and has opened a waitlist for its initial rollout. Clinical services are currently provided through partner DocTap, and Calibre has submitted its own CQC application to deliver care directly. Founders include Alexander Weber (formerly early team and Chief Growth Officer at N26), Ben Levy (experienced software and healthtech executive), and Dr Reinhold Innerhofer (medical doctor and sports scientist). Calibre raised $3.3M in pre-seed funding to support its launch and growth.

• Condukt

  Participated · Seed · Nov 2025

  Founded in May 2023, London-based Condukt has built an agentic, real-time compliance infrastructure that continuously synchronises with a customer’s operations and open-source data. The platform replaces manual, periodic checks with automated monitoring that flags risk changes as they occur, helping institutions keep pace with tightening anti-money-laundering enforcement. Condukt’s proprietary data layer powers actionable insights across know-your-business (KYB) and wider financial-crime compliance workflows, aiming to reduce both cost and operational drag. Early customers include prominent fintechs such as Wise, Tide, Mollie, Rakuten, Shift4, Flatpay and myPOS. By embedding live compliance into daily operations, the company positions regulatory adherence as a growth and trust lever rather than a cost centre. The newly raised capital will be directed toward deepening partnerships with major financial institutions, expanding go-to-market efforts, and scaling its engineering team.

• Cyclana Bio

  Participated · Seed · Oct 2025

  Cyclana Bio is pioneering the creation of physiologically relevant, whole-tissue disease models that capture the complex interactions between cells and the extracellular matrix (ECM). Using menstrual-fluid samples from an observational clinical trial and in-lab modelling, the company uncovers early biomarkers and identifies novel, druggable targets for endometriosis. Its platform combines these tissue models with AI-powered multi-scale data integration to reveal mechanisms that intracellular-focused approaches have missed. The founding scientific team, led by CSO Prof. Kevin Chalut and CEO Dr. Léa Wenger, has already demonstrated that ECM dysregulation drives inflammation and tissue dysfunction in endometriosis. Cyclana Bio plans to expand its methodology to other underserved chronic inflammatory diseases that share similar tissue-level mechanisms. Financially, the company has secured £5 million in pre-seed capital to advance platform development and disease-model validation.

No current team members are available.